Zobrazeno 101 - 110
of 16 691
pro vyhledávání: ''
Autor:
Konstantin Penkov, Taofeek K. Owonikoko, Peter M. Ellis, Bruce A. Bach, Anne Sibille, Vasudha Sehgal, Choon Hee Son, Lei He, Jaimee Glasgow, Harry J.M. Groen, Junya Fujimoto, Patricia M. de Groot, Kingston Kang, Martin Dunbar, Lauren Averett Byers, Steven J. M. Gans, Dmitry Bentsion
Publikováno v:
Clinical Cancer Research, 27(14), 3884-3895. AMER ASSOC CANCER RESEARCH
Purpose: This study investigated the efficacy and safety of oral PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-SCLC). Patients and Methods: Patients were randomi
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1806-1809
Introduction Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs ha
Autor:
Alberto Zaniboni, Chiara Cremolini, Gianluca Tomasello, Samanta Cupini, Laura Fanchini, Beatrice Borelli, Sara Lonardi, Gianluca Masi, Daniele Rossini, Angela Buonadonna, Carlotta Antoniotti, Veronica Conca, Gemma Zucchelli, Alfredo Falcone, Federica Marmorino, Margherita Ambrosini, Salvatore Caponnetto, Daniele Santini, Cosimo Rasola, Roberto Moretto
Publikováno v:
Br J Cancer
BACKGROUND: In mCRC, CEA is used to monitor response to systemic therapy together with imaging. After the end of induction, no major improvement in tumour shrinkage is expected, and the availability of a marker able to predict progressive disease (PD
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Autor:
Xin Li, Ting Yuan, Rui Sun, Xia Xiong, Yunxiong Wei, Hairong Lyu, Xin Jin, Ming-Feng Zhao, Wenyi Lu, Xiaoyuan He, Tongtong Sun
Publikováno v:
Cancer Science
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curative option for patients su
Autor:
Saad Sheikh, Sujay Datta, Tithi Biswas, Charulata Jindal, Mitchell Machtay, Tarun Podder, Afshin Dowlati, Asoke Dey, Jimmy T. Efird
Publikováno v:
Future Oncology. 17:2713-2724
The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients with extensive-stage sm
Autor:
Richard Greil, Armin Gerger, Renate Schaberl-Moser, Martin Pichler, Dominik A. Barth, Michael Stotz, Angela Djanani, Antonia Gantschnigg, Lena Horvath, Jakob M. Riedl, Herbert Stöger, Felix Renneberg, Konstantin Schlick, Christopher Rossmann, Florian Posch, Esther Schwarzenbacher, Florian Moik
Publikováno v:
European Journal of Cancer. 151:3-13
Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has ye
Autor:
Rebeca Lozano, Gerhardt Attard, Ugo De Giorgi, Enrique Gonzalez-Billalabeitia, Giuseppe Schepisi, Isabel M. Aragón, Vincenza Conteduca, David Olmos, Daniel Wetterskog, Begoña Mellado, Nuria Romero-Laorden, Nicole Brighi, Emanuela Scarpi, Anuradha Jayaram, Cristian Lolli, Chiara Casadei, Mercedes Marín-Aguilera, Elena Castro, Giorgia Gurioli, Anna Wingate
Publikováno v:
Università degli studi di Foggia-IRIS
Background: Plasma AR status has been identified as a potential biomarker of response in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel or AR-targeted therapies. However, the relevance of plasma AR in the overall
Autor:
Geraldine M. Jacobson, Gary Marano, Timothy D. Eubank, Malcolm D. Mattes, Patrick C. Ma, Mohammed Almubarak, Sijin Wen
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: This study assessed the safety and systemic (abscopal) response from the addition of local stereotactic body radiation therapy (SBRT) to checkpoint inhibitor (CPI) immunotherapy in patients with metastatic non-small cell lung
Autor:
Reza Sari Motlagh, Jeremy Yuen-Chun Teoh, Shin Egawa, Benjamin Pradere, Ekaterina Laukhtina, Thomas Powles, Keiichiro Mori, Victor M. Schuettfort, Marco Moschini, Francesco Soria, Shahrokh F. Shariat, Hadi Mostafaei
Publikováno v:
European Journal of Cancer. 151:35-48
Introduction Platinum-based combination chemotherapy is the standard treatment for patients with chemotherapy-eligible metastatic urothelial carcinoma (mUC). Immune-checkpoint inhibitors (ICIs) are currently assessed in this setting. This review aime